MENU
Aim higher

DEPSTER

The pregnenolone-derivative MAP4343 as a new therapy for the treatment of depressive disorders: a preclinical project

Current antidepressant treatments are inadequate to rescue the brain structural alterations reported in depressed individuals. MAP4343 is an innovative neuronal plasticity modulator showing potential antidepressant efficacy. DEPSTER will validate the use MAP4343 as a novel therapy for depression.
Acronym: 
DEPSTER
Project ID: 
5 291
Ranking: 
6
Cut-off: 
3
Start date: 
04-01-2010
Project Duration: 
30months
Project costs: 
2 170 850.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Therapeutic